LifeMD (LFMD)
Nasdaq Market Closed
LifeMD, Inc. is a direct-to-patient healthcare company that delivers virtual medical care, pharmacy services, and related health programmes through a telehealth model. The company connects patients with licensed medical providers and supports treatment access through a combination of digital intake tools, patient care operations, pharmacy infrastructure, and direct marketing. Its model is designed to make routine and ongoing care more convenient for consumers who prefer remote consultations and home delivery of prescribed therapies.
LifeMD’s continuing operations are organised around telehealth. The platform supports services across areas such as primary care, men’s health, dermatology, weight management, and other recurring treatment categories where virtual engagement can reduce friction for patients. The company uses its own commercial pharmacy capabilities alongside a wider nationwide pharmacy network, allowing it to coordinate prescribing, fulfilment, and patient support more directly than many asset-light telehealth providers.
A key feature of LifeMD’s business is its vertically integrated approach. It combines consumer acquisition, clinical workflows, patient care centre operations, pharmacy access, and AI-enabled technology intended to improve efficiency and retention. This structure gives the company more control over the patient experience, from initial marketing contact through consultation, prescription management, and follow-up care.
For investors, LFMD offers exposure to the evolving market for digital healthcare and consumer-driven medical services. Its performance depends on patient acquisition costs, subscription and repeat-use behaviour, provider network quality, pharmacy execution, regulatory compliance, and the ability to expand care categories while maintaining clinical standards. The company sits at the intersection of telemedicine, online pharmacy, and personalised consumer healthcare.
Last updated
- Market Cap
- 226.82M
- P/E
- 107.81
- P/FCF
- 59.65
- P/S
- 1.26
- Enterprise Value
- 192.34M
- Sector
- Health Care
- Industry
- Offices and Clinics of Doctors of Medicine
- Address
- 236 FIFTH AVENUE, NEW YORK, NY, 10001
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
LifeMD® to Offer Market-Leading Pricing for GLP-1 Medications Wegovy® and Ozempic® in Continued Collaboration with Novo Nordisk
Non-Sterile Compounding Pharmacy Market Size Expected to Reach USD 12.11 Bn by 2034
TLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
LFMD INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that LifeMD, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
LIFEMD CLASS ACTION DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urges LifeMD Investors to Contact the Firm Before October 27th Regarding Filed Class Action
מחר המועד אחרון לתביעה נגד LFMD: רוזן, משרדי עורכי דין מכובד ברחבי העולם, מעודד את משקיעי LifeMD, Inc. להשיג ייעוץ לפני המועד האחרון החשוב של 27 באוקטובר בתביעה ייצוגית בניירות ערך שהוגשה ראשונה על ידי המשרד – LFMD
LFMD DEADLINE TOMORROW: ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages LifeMD, Inc. Investors to Secure Counsel Before Important October 27 Deadline in Securities Class Action First Filed by the Firm – LFMD
LFMD 2-DAY DEADLINE ALERT: Lawsuit Targets Telehealth Firm LifeMD (LFMD) Over Alleged Misleading Statements -- Hagens Berman
LFMD INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that LifeMD, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
LIFEMD DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages LifeMD, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – LFMD
LFMD 9-DAY DEADLINE ALERT: Lawsuit Targets Telehealth Firm LifeMD (LFMD) Over Alleged Misleading Statements -- Hagens Berman
DEADLINE ALERT for AI, LFMD, SMLR, DOW: Law Offices of Howard G. Smith Reminds Shareholders of Opportunity to Lead Securities Fraud Class Actions
LFMD INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that LifeMD, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
LFMD DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages LifeMD, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – LFMD
LFMD DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages LifeMD, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – LFMD
LFMD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of LifeMD
DEADLINE ALERT for AI, LFMD, SMLR, DOW: Law Offices of Howard G. Smith Reminds Shareholders of Opportunity to Lead Securities Fraud Class Actions
LIFEMD DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages LifeMD, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – LFMD
LFMD INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that LifeMD, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 226.82M
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 192.34M
- P/E
P/E ratio compares a company's share price to its earnings per share.
- 107.81
- P/B
P/B ratio compares a company's share price to its book value per share.
- 15.08
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 1.26
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- -16.9
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 1.07
- EPS
- 0.04
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 2.4%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- 59.65
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- 40.1
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- 3.8M
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- 13.99%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- 3%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 1.04
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 0.98
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 0.7
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 1.03M
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 4.69
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | 50.16M | 7.08M | 60.17M | 62.22M | 50.89M |
| Gross profit | 44.24M | 2.85M | 52.76M | 54.79M | 42.75M |
| Operating income | -8.93M | -6.22M | -1.97M | -906.77K | -1.18M |
| EBITDA | -6.93M | -7.39M | 1.02M | 1.92M | 509.69K |
| Net income | -9.65M | 19.19M | -4.58M | -2.85M | -960.34K |
| Basic EPS | -0.2 | 0.43 | -0.1 | -0.06 | -0.02 |
| Diluted EPS | -0.2 | 0.43 | -0.1 | -0.06 | -0.02 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 70.12M | 70.41M | 65.98M | 73.56M | 73.61M |
| Total liabilities | 55.09M | 47.25M | 62.62M | 73.18M | 74.01M |
| Total equity | 15.04M | 23.16M | 3.37M | 382.38K | -392.75K |
| Cash & equivalents | 34.48M | 36.79M | 23.79M | 36.23M | 34.39M |
| Current assets | 51.7M | 51.83M | 41.09M | 49.03M | 49.78M |
| Current liabilities | 49.59M | 41.57M | 56.66M | 63.53M | 60.9M |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | 444.62K | -3.28M | -147.14K | 8.64M | 3.07M |
| Investing cash flow | -2.06M | 17.07M | -3.59M | -3.7M | -2.87M |
| Financing cash flow | -696.04K | -788.56K | -8.7M | -3.1M | -812.56K |
| Change in cash | -2.31M | 13M | -12.44M | 1.83M | -611.51K |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 4 — LifeMD, Inc. | View Filing | |
| form 4 | Form 4 — Kavthekar Atul | View Filing | |
| edgar index | 8-K — LifeMD, Inc. | View Filing | |
| edgar index | 10-Q — LifeMD, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 3 — LifeMD, Inc. | View Filing | |
| edgar index | 3 — LifeMD, Inc. | View Filing | |
| edgar index | 4 — LifeMD, Inc. | View Filing | |
| edgar index | S-8 — LifeMD, Inc. | View Filing | |
| form 4 | Form 4 — Pisano Christopher A | View Filing | |
| edgar index | 144 — LifeMD, Inc. | View Filing | |
| edgar index | 8-K — LifeMD, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 10-K — LifeMD, Inc. | View Filing | |
| ten k section | 10-K — business | View Filing | |
| ten k section | 10-K — mda | View Filing | |
| ten k section | 10-K — risk_factors | View Filing | |
| edgar index | 8-K — LifeMD, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — LifeMD, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — LifeMD, Inc. | View Filing | |
| form 4 | Form 4 — FRIEDEMAN JESSICA | View Filing | |
| edgar index | 144 — LifeMD, Inc. | View Filing | |
| edgar index | 8-K — LifeMD, Inc. | View Filing | |
| edgar index | 10-Q — LifeMD, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | NT 10-Q — LifeMD, Inc. | View Filing | |
| edgar index | 8-K — LifeMD, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — LifeMD, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — LifeMD, Inc. | View Filing | |
| edgar index | 4 — LifeMD, Inc. | View Filing | |
| edgar index | 4 — LifeMD, Inc. | View Filing | |
| edgar index | 4 — LifeMD, Inc. | View Filing | |
| edgar index | 4 — LifeMD, Inc. | View Filing | |
| form 4 | Form 4 — LAROVERE JOAN | View Filing | |
| form 4 | Form 4 — Strawn John R Jr | View Filing | |
| form 4 | Form 4 — Strawn John R Jr | View Filing | |
| form 4 | Form 4 — Simon Roberto | View Filing | |
| form 4 | Form 4 — MACRAE CALUM ARCHIBALD | View Filing | |
| form 4 | Form 4 — DiTrolio Joseph | View Filing | |
| edgar index | 4 — LifeMD, Inc. | View Filing | |
| edgar index | 144 — LifeMD, Inc. | View Filing | |
| form 4 | Form 4 — Alvarez Nicholas P | View Filing | |
| edgar index | 4 — LifeMD, Inc. | View Filing | |
| edgar index | 4 — LifeMD, Inc. | View Filing | |
| edgar index | 4 — LifeMD, Inc. | View Filing | |
| edgar index | 4 — LifeMD, Inc. | View Filing | |
| edgar index | 4 — LifeMD, Inc. | View Filing | |
| edgar index | 4 — LifeMD, Inc. | View Filing | |
| edgar index | 4 — LifeMD, Inc. | View Filing | |
| edgar index | 4 — LifeMD, Inc. | View Filing | |
| form 4 | Form 4 — Dray Shayna Webb | View Filing | |
| form 4 | Form 4 — Alvarez Nicholas P | View Filing | |
| form 4 | Form 4 — Benathen Marc David | View Filing | |
| form 4 | Form 4 — FRIEDEMAN JESSICA | View Filing | |
| form 4 | Form 4 — Galluppi Stefan | View Filing | |
| form 4 | Form 4 — Galluppi Stefan | View Filing | |
| form 4 | Form 4 — STAN MARIA E. | View Filing | |
| form 4 | Form 4 — Wijnker Dennis | View Filing | |
| form 4 | Form 4 — Yecies Eric Harold | View Filing | |
| edgar index | 8-K — LifeMD, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — LifeMD, Inc. | View Filing | |
| edgar index | 8-K — LifeMD, Inc. | View Filing | |
| edgar index | 10-Q — LifeMD, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 144 — LifeMD, Inc. | View Filing | |
| form 4 | Form 4 — Schreiber Justin | View Filing | |
| form 4 | Form 4 — Schreiber Justin | View Filing | |
| form 4 | Form 4 — Schreiber Justin | View Filing | |
| edgar index | 3 — LifeMD, Inc. | View Filing | |
| edgar index | 4 — LifeMD, Inc. | View Filing |